Daiichi Sankyo To Revamp Prasugrel's U.S. Marketing After Sluggish Sales
This article was originally published in PharmAsia News
Executive Summary
TOKYO - An 11.1 percent upward operating income revision to ¥100 billion notwithstanding, Daiichi Sankyo is streamlining its U.S. marketing strategy for platelet inhibitor Effient (prasugrel) as the drug's July-September U.S. and European sales remained a humble ¥1.8 billion, a company spokesman said Nov. 2